Loading patent…
AssigneeGenomatica, Inc.
InventorsMichael A. Noble, Russell Scott Komor, Jingyi Li
Estimating the term…
Described herein are non-natural olivetol synthase (OLS) variants, nucleic acids, engineered cells, method s for preparing cannabinoids, and compositions thereof. The non-natural olivetol OLS variants form desired cannabinoid precursor and products at increased rates, have higher affinity for pathway substrates, and/or byproducts are formed in lower amounts in their presence, as compared to wild type OLS. The OLS variants can be used to form linear polyketides, and can be expressed in an engineered cell having a pathway to form cannabinoids, which include CBGA, its analogs and derivatives. CBGA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.
A non-natural olivetol synthase (OLS) comprising at least one amino acid variation as compared to a wild type olivetol synthase, wherein the non-natural olivetol synthase:
3-7. (canceled)
9-11. (canceled)
The non-natural olivetol synthase of claim 13, wherein the non-natural olivetol synthase comprises at least two amino acid variations as compared to a wild type olivetol synthase, or at least three, four, five, or more amino acid variations as compared to a wild type olivetol synthase.
(canceled)
(canceled)
(canceled)
21-25.(canceled)
(canceled)
30-32. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
44-46. (canceled)
48-51. (canceled)
53-57. (canceled)
A composition comprising a cannabinoid, analogs, or derivatives thereof, or combinations thereof obtained from the method of claim 49, wherein the composition comprises olivetol or analogs and derivatives of olivetol, pentyl diacetic acid lactone (PDAL), hexanoyl triacetic acid lactone (HTAL), a lactone analog, or a combination thereof at a concentration of no more than about 0.1% to about 0.0001% by weight of the composition.
59-62. (canceled)
Dependencies are inferred from the claim text.